News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Syntara.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: With its last patient treated, Opthea eyes pending results of do-or-die trial
Health & Biotech
Health Check: Despite a ‘biggest ever’ December half, Pro Medicus says it’s just revving up in the US
Health & Biotech
ASX healthcare leaders wear many hats in interconnected sector
Health & Biotech
Health Check: Local biotech starred in 2024, but the rising tide did not lift all boats
Health & Biotech
Scott Power: The lowdown on Sonic’s $700m German excursion
Health & Biotech
Health Check: Can Syntara produce the next multibillion-dollar Aussie blood cancer drug?
Health & Biotech
Health Check: The robots are taking over biotech stock selection
Stockhead TV
Tony’s Takeaway: Summertime stocks
Health & Biotech
Health Check: Biotech’s forgotten tortoises pick up the pace as sector emerges from two-year slump
Health & Biotech
Health Check: Hold the front page for a rush of clinical trial updates
Investor Guides
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
News
Rise and Shine: Everything you need to know before the ASX opens
News
Hot Money Tuesday: Momentum signals good entry points for Atlas Pearls, Andromeda, and AJ Lucas
News
Closing Bell: ASX down but smiles all round after surprise M&A Monday
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but Dimerix up 150% on drug licensing deal
News
Rise and Shine: Everything you need to know before the ASX opens
News
